Laforin/EPM2A Antibody (523435) [Alexa Fluor® 350]

• Reactivity: Hu
• Applications: WB
• Clone: 523435
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 350

Laforin/EPM2A Antibody (523435) [Alexa Fluor® 350] Summary

• Immunogen: E. coli-derived recombinant human Laforin/EPM2A
  Met1-Leu331
  Accession # AAH70047
• Specificity: Detects human Laforin/EPM2A in Western blots.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Laforin/EPM2A Antibody (523435) [Alexa Fluor® 350]

• EC 3.1.3.16
• EC 3.1.3.48
• epilepsy, progressive myoclonus type 2, Lafora disease (laforin)
• epilepsy, progressive myoclonus type 2A, Lafora disease (laforin)
• EPM2
• EPM2A
• Lafora PTPase
• Laforin
• LAFPTPase
• LD
• LDE
• MELF

Background

Laforin, also known as Lafora PTPase and EPM2A, is a 38 kDa member of the protein tyrosine phosphatase family. Human Laforin is 331 aa in length and contains one carbohydrate binding type-20 (CBM20) domain (aa 1-124) and one tyrosine-protein phosphatase domain (aa 243-311). Multiple splicing variants produce four isoforms of human Laforin, which is most highly expressed in heart, skeletal muscle, kidney, pancreas and brain. It functions as a dual specificity protein phosphatase and may be involved in the control of glycogen metabolism. Mutations in Laforin cause progressive myoclonic epilepsy type 2, also known as Lafora disease.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.